Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (886)	2/5/2002 1:38:03 PM
From: scaram(o)uche	Respond to of 2243

Thanks for the posts, Ice. If everyone could cut and paste as they dive into Edgar, it would be appreciated. My first blush opinion..... they've combined niche products and license income with legal, highly leveraged and risky development-stage biotech investments. The business plan...... diversification across a large cross section of the drug development (discovery and delivery) process, with some great investments (not all!). A huge, adequately described, well managed, and legal Ponzi scheme. If Merck could buy them tomorrow for $10 billion, it would be a very wise thing to do. Again, this is first blush. And there are lots of people out there who would like to destroy the company to secure further short profit. At four times this market cap, I wasn't interested. Even down here, it's apparent that investors have lost their desire to reach and dream. Imclone. Ugh. Tuesday February 5, 10:36 am Eastern Time Repentant Companies Find No Mercy By James J. Cramer Brutal market. Take Elan (NYSE:ELN - news). It was damned if it kept up with these Lazy Susan partnerships , where it gives money to an off-the-books entity and then it takes money back and books it as revenue. And it was damned when it decided to make a clean breast of things. ... ( This article continues for RealCommentary subscribers...)